Proteasome inhibitor primes temozolomide response in a molecular subset of recurrent glioblastoma
An interim analysis of the BORTEM-17 phase IB/II trial found that sequential bortezomib and temozolomide achieved disease control in four ...
Tag: CDKN2A/RB1
